[Is high tumor mutation burden predictive of immune checkpoint blockade efficacy in terms of overall survival across all cancer types?]

Bull Cancer. 2021 Jun;108(6):669-671. doi: 10.1016/j.bulcan.2021.04.001. Epub 2021 May 10.
[Article in French]
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Humans
  • Immune Checkpoint Inhibitors*
  • Mutation
  • Neoplasms* / drug therapy
  • Neoplasms* / therapy

Substances

  • Immune Checkpoint Inhibitors